Chlamydia pneumoniae

 

Chlamydia pneumoniae is a small gram-negative bacterium (0.2 to 1 μm) that undergoes several transformations during its life cycle. It exists as an elementary body (EB) between hosts. The EB is not biologically active, but is resistant to environmental stresses and can survive outside a host for a limited time. The EB travels from an infected person to the lungs of an uninfected person in small droplets and is responsible for infection. Once in the lungs, the EB is taken up by cells in a pouch called an endosome by a process called phagocytosis. However, the EB is not destroyed by fusion with lysosomes, as is typical for phagocytosed material. Instead, it transforms into a reticulate body (RB) and begins to replicate within the endosome. The reticulate bodies must use some of the host's cellular metabolism to complete its replication. The reticulate bodies then convert back to elementary bodies and are released back into the lung, often after causing the death of the host cell. The EBs are thereafter able to infect new cells, either in the same organism or in a new host. Thus, the lifecycle of C. pneumoniae is divided between the elementary body, which is able to infect new hosts but cannot replicate, and the reticulate body, which replicates but is not able to cause a new infection.^[9]

Chlamydia pneumoniae is a common cause of pneumonia around the world; it is typically acquired by otherwise-healthy people and is a form of community-acquired pneumonia. Its treatment and diagnosis are different from historically recognized causes, such as Streptococcus pneumoniae.^[10] Because it does not gram stain well, and because C. pneumoniae bacteria is very different from the many other bacteria causing pneumonia (in the earlier days, it was even thought to be a virus), the pneumonia caused by C. pneumoniae is categorized as an "atypical pneumonia".^[11]

One meta-analysis of serological data comparing prior C. pneumoniae infection in patients with and without lung cancer found results suggesting prior infection was associated with an increased risk of developing lung cancer.^[12][13][14]

In research into the association between C. pneumoniae infection and atherosclerosis and coronary artery disease, serological testing, direct pathologic analysis of plaques, and in vitro testing suggest infection with C. pneumoniae is a significant risk factor for development of atherosclerotic plaques and atherosclerosis.^[15] C. pneumoniae infection increases adherence of macrophages to endothelial cells in vitro and aortas ex vivo.^[16] However, most current research and data are insufficient and do not define how often C. pneumoniae is found in atherosclerotic or normal vascular tissue.^[17]

Chlamydia pneumoniae has also been found in the cerebrospinal fluid of patients diagnosed with multiple sclerosis.^[18]

Chlamydia pneumoniae infection was first associated with wheezing, asthmatic bronchitis, and adult-onset asthma in 1991.^[19] Subsequent studies of bronchoalveolar lavage fluid from pediatric patients with asthma and also other severe chronic respiratory illnesses have demonstrated that over 50 percent had evidence of C. pneumoniae by direct organism identification.^[20][21] C. pneumoniae infection triggers acute wheezing, if it becomes chronic then it is diagnosed as asthma.^[22] These observations suggest that acute C. pneumoniae infection is capable of causing protean manifestations of chronic respiratory illness which lead to asthma.^[23]

Macrolide antibiotic treatment can improve asthma in a subgroup of patients that remains to be clearly defined. Macrolide benefits were first suggested in two observational trials^[24][25] and two randomized controlled trials^[26][27] of azithromycin treatment for asthma. One of these RCTs^[27] and another macrolide trial^[28] suggest that the treatment effect may be greatest in patients with severe, refractory asthma. These clinical results correlate with epidemiological evidence that C. pneumoniae is positively associated with asthma severity^[29] and laboratory evidence that C. pneumoniae infection creates steroid-resistance.^[30] A meta analysis of 12 RCTs of macrolides for the long term management of asthma found significant effects on asthma symptoms, quality of life, bronchial hyper reactivity and peak flow but not FEV1.^[31] More recent positive results of long-term treatment with azithromycin on asthma exacerbations and quality-of-life in patients with severe, refractory asthma^[32][33] have resulted in azithromycin now being recommended in international guidelines as a treatment option for these types of patients.^[34]

A recent case series of 101 adults with asthma reported that macrolides (mostly azithromycin) and tetracyclines, either separately or in combination, appeared to be dramatically efficacious in a subgroup of "difficult-to-treat" (i.e., not necessarily refractory to high-dose inhaled corticosteroids but who did not take them) patients with severe asthma, many of whom also had the "overlap syndrome" (asthma and COPD).^[35] Randomized, controlled trials that include these types of asthma patients are needed.

Chlamydia pneumoniae infection has been associated with schizophrenia.^[36] Many other pathogens have been associated with schizophrenia as well.^[36] Chronic Chlamydia pneumoniae infection has also in some cases been found to be a cause of chronic fatigue syndrome (CFS) that can be resolved with antibiotics.^[37][38]

The first-line antibiotics for treatment of Chlamydia pneumoniae are the macrolide erythromycin and the tetracyclines tetracycline and doxycycline.^[39] The macrolides clarithromycin and azithromycin are also effective.^[39] Chlamydia pneumoniae shows resistance to penicillin, ampicillin, and sulfa drugs, and hence these antibiotics are not recommended.^[39] Other antibiotics which may be effective include fluoroquinolones like levofloxacin, gatifloxacin, gemifloxacin, and moxifloxacin.^[39] Symptoms of Chlamydia pneumoniae often reappear after short or conventional courses of antibiotics.^[39] As a result, following confirmation of persistent infection with culture, intensive long-term treatment is recommended.^[39]

There is currently no vaccine to protect against Chlamydia pneumoniae. Identification of immunogenic antigens is critical for the construction of an efficacious subunit vaccine against C. pneumoniae infections. Additionally, there is a general shortage worldwide of facilities that can identify/diagnose Chlamydia pneumoniae.^{[citation needed]}

• Chlamydia Pneumoniae cpnhelp.org Archived 2022-07-05 at the Wayback Machine
• Type strain of Chlamydopila pneumoniae at BacDive - the Bacterial Diversity Metadatabase